# Contact TB-500 Compound: Editorial Inquiries and Source Corrections

> Contact TB-500 Compound about the editorial content or to flag a citation correction. An editorial research digest on TB-500 — not a clinic, not a vendor, and not a source for the compound.

For corrections, source questions, and editorial inquiries about the TB-500 literature digest.

## Editorial inquiries

Use the form below to reach TB-500 Compound about the editorial content of this site. We welcome citation corrections, pointers to peer-reviewed studies we have missed, and questions about how a particular claim is sourced. If you believe a finding has been attributed to the wrong molecule — fragment versus full-length thymosin β4 — tell us which entry and we will check it against the source.

We cannot help with anything outside the editorial record. We do not provide medical advice, we do not recommend or supply TB-500, and we cannot direct you to a clinic, pharmacy, or vendor. Questions about obtaining the compound fall outside what this project does and will not receive a sourcing reply.

## What we are not

This is an editorial research digest. It is not a clinic, not a compounding pharmacy, and not a sales channel. Nothing here is dispensed, prescribed, or sold. For the regulatory picture on compounded access in general terms, see the [TB-500 legal status and 503A category](/legal-status) page; for the full source list, see the [TB-500 references and citations](/references) register. For medical questions about your own situation, consult a licensed healthcare professional — not this site.

---

A cool-green research board for the TB-500 record — the Ac-LKKTETQ fragment routed as its own net apart from the full-length thymosin beta-4 it is sold as, the empty human-trial pad left open, the tumor-angiogenesis trace flagged and the FDA 503A standing read first; no clinic solders this board and nothing here is dispensed or sold.